---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ACTRN12621000011886"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: ACTRN12621000011886. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 46 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/actrn12621000011886"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ACTRN12621000011886

<a id="heading-3.1.6"></a>

## 3.1.6 ACTRN12621000011886

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Aims of the first-in-human and multiple-dose studies

> “The aim of the studies was to assess the safety, tolerability, PK, pharmacodynamics (PD), and the effect of a high‐calorie breakfast of single and multiple oral doses of ESK‐001 in healthy adult participants.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.1-2"></a>

#### Dose-finding purpose of the wide dose range

> “The wide dose ranges chosen in this study aimed to identify the safest and most tolerable dose while achieving maximum PD target engagement and to support dose selection for phase II studies.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Study period and site of the first-in-human study in the publication

> “This was a first‐in‐human, phase I, single‐center, randomized, double‐blinded, placebo‐controlled, single (SAD) and multiple ascending dose (MAD) study of oral ESK‐001 administration in healthy participants (ACTRN12621000011886), conducted between January 21, 2021 and February 24, 2022 at a facility in Adelaide (Australia).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.2-2"></a>

#### Registration, enrollment, and data collection dates in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Date submitted | “26/11/2020” |
| Date registered | “11/01/2021” |
| Type of registration | “Prospectively registered” |
| Recruitment status | “Completed” |
| Date of first participant enrolment, anticipated | “29/01/2021” |
| Date of first participant enrolment, actual | “17/02/2021” |
| Date of last participant enrolment, anticipated | “17/11/2021” |
| Date of last participant enrolment, actual | “19/01/2022” |
| Date of last data collection, anticipated | “30/11/2021” |
| Date of last data collection, actual | “4/02/2022” |
| Date last updated | “14/06/2022” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.2-3"></a>

#### Recruitment state and principal investigator site in Adelaide, Australia, in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Recruitment state(s) | “SA” |
| Principal investigator | “Prof Sepehr Shakib” |
| Principal investigator address | “CMAX Clinical Research Pty Ltd Level 5, 18 a North Terrace Adelaide, SA, 5000 Australia” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.2-4"></a>

#### Results documents and data sharing in the ANZCTR record

> “No documents have been uploaded by study researchers.”

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

| Field | Quoted record |
| --- | --- |
| Will the study consider sharing individual participant data? | “No” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Study type, allocation, control, and phase in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Health condition(s) studied | “Psoriasis” |
| Study type | “Interventional” |
| Purpose of the study | “Treatment” |
| Allocation to intervention | “Randomised controlled trial” |
| Control group | “Placebo” |
| Phase | “Phase 1” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.3-2"></a>

#### Secondary sponsor, funding, and ethics approval in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Funding source category | “Commercial sector/Industry” |
| Secondary sponsor name | “Avance Clinical Pty Ltd” |
| Ethics committee name | “Bellberry Human Research Ethics Committee” |
| Ethics approval date | “10/12/2020” |
| Ethics approval number | “2020-11-1116” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.3-3"></a>

#### Regulatory framework of the Australian study

> “The study adhered to the applicable regulations of the Australian Therapeutic Goods Administration under the Clinical Trial Notification scheme, the principles of the Declaration of Helsinki, the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6 (R2) Good Clinical Practice – Scientific Guideline, and the National Health and Medical Research Council National Statement on Ethical Conduct in Human Research.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.3-4"></a>

#### Blinding and randomization procedures

> “The Sponsor, Principal Investigator, clinical study personnel, and study participants were blinded to treatment.”
> “Any analysis of PK and PD data prior to unblinding was performed by the unblinded bioanalytical laboratory and pharmacokineticist at Avance Biometrics who had no responsibility for data monitoring and management in the study.”
> “The data were reblinded before being provided to any study personnel who were to remain blind.”
> “Randomization was prepared by unblinded statisticians using SAS Version 9.4 (or higher), provided to pharmacy staff involved in study drug dispensing, and maintained in a restricted access area.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.3-5"></a>

#### Single ascending dose part: confinement, escalation, and 3:1 randomization

> “In the SAD part, the screening period from Day −28 to −2 was followed by admission of the participants to the facility from Day −1 to 3 (Day 4 for Cohort 25 mg) with dose administration on Day 1 and final safety assessments on Day 7 ± 2.”
> “Dose escalation was based on the safety and PK results of the previous dose cohort.”
> “Participants were randomized to six cohorts (planned cohort size: 8 participants) to receive a single oral dose of ESK‐001 or placebo (3:1) in fasted conditions.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.3-6"></a>

#### Food effect cohort: two periods separated by a washout

> “Eight participants were allocated to the food effect (FE) cohort and were admitted to the facility from Day −1 to 8, with the first study drug administration on Day 1 (Period 1), followed by a 5‐day washout period and second dose administration on Day 6 (Period 2).”
> “Final safety assessments occurred on Day 12 ± 2.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.3-7"></a>

#### Single ascending dose cohorts in the congress poster's design schematic

> “ESK-001: liquid formulation”
> “Cohorts 1 to 5: fasted, active (n=6), placebo (n=2)”
> “Part A from Study ACTRN12621000011886”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Age, body mass index, and health criteria in the published report

> “Eligible participants included adult men and women, aged 18–55 years (SAD/MAD) or 18–60 years (MD), with a BMI of 18.0–32.0 kg/m2, body weight ≥50 kg (SAD/MAD), and medically healthy as determined by physical examination, vital signs, conventional 12‐lead electrocardiogram (ECG), and routine laboratory parameters.”
> “Women were of nonchildbearing potential or had a negative pregnancy test if childbearing potential and were not lactating.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.4-2"></a>

#### Key inclusion criteria and age limits in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Body mass index and weight | “Body mass index greater than or equal to 18.0 and less than or equal to 32.0 kg/m2, with a body weight greater than or equal to 50 kg at screening.” |
| Smoking | “Be nonsmokers (including tobacco, e-cigarettes and marijuana) for at least 3 months prior to first study drug administration and have a negative test for cotinine at the Screening visit and at check-in on Day -1.” |
| Health status | “Medically healthy without clinically significant abnormalities at the screening visit, at check-in on Day -1 and pre-dose on Day 1” |
| Electrocardiogram | “Conventional 12-lead ECG recording in triplicate consistent with normal cardiac conduction and function” |
| Minimum age | “18 Years” |
| Maximum age | “55 Years” |
| Sex | “Both males and females” |
| Healthy volunteers | “Yes” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.4-3"></a>

#### Key exclusion criteria in the ANZCTR record

| Criterion | Quoted record |
| --- | --- |
| Significant disease | “History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the past 3 months determined by the PI to be clinically relevant.” |
| Current infection | “Current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medications.” |
| Malignancy | “Any history of malignant disease in the last 10 years (excludes surgically resected skin squamous cell or basal cell carcinoma).” |
| Immunosuppression | “Presence of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.” |
| Immunosuppressive or immunomodulating medications | “Use of or plans to use systemic immunosuppressive (e.g., corticosteroids, methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g., interferon) during the study or within 3 months prior to the first study drug administration.” |
| Skin findings | “Presence or evidence of recent sunburn, scar tissue, tattoo (more than 25% of body area), open sore, or branding that, in the opinion of the Investigator, would interfere with interpretation of skin adverse reaction assessments.” |
| Liver function tests | “Liver function test results elevated more than 1.5-fold above the upper limit of normal (ULN) for gamma glutamyl transferase [GGT], bilirubin (total, conjugated and unconjugated) or alkaline phosphatase (ALP) or elevated 2.0-fold above ULN for aspartate aminotransferase (AST) or alanine aminotransferase (ALT).” |
| Viral infection | “Positive test results for active human immunodeficiency virus (HIV-1 and HIV-2), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at the screening visit.” |
| Tuberculosis | “History of active, latent or inadequately treated tuberculosis infection.” |
| Conditions affecting drug disposition | “Presence or having sequelae of gastrointestinal, liver (including Gilbert’s syndrome), kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.” |
| Renal function | “Estimated creatinine clearance (CrCl) < 60 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.” |
| Concomitant medication | “Use of any systemically absorbed prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 10 days or 5 half-lives of the medication (whichever is longer) prior to the first study drug administration, except occasional use of paracetamol (up to a maximum of 4 doses per day of 500-mg paracetamol, and no more than 3g per week).” |
| Interferon hypersensitivity | “Known hypersensitivity to interferon alfa or any component of the product (Part B only).” |
| Vaccination | “Use of any vaccinations within 30 days prior to the first study drug administration.” |
| Other investigational trials | “Participation in another investigational clinical trial within 60 days (or 5 half-lives, of the investigational agent) (whichever is longer) prior to the first study drug administration.” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### Liquid formulation and matching placebo

> “The active treatment was a liquid formulation of ESK‐001 (Batch number: JR‐C200609006‐FPF20001), while placebo contained the same excipients as the active treatment, with denatonium benzoate (Batch number: R086X0) instead of ESK‐001.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.5-2"></a>

#### Planned and actual single ascending dose levels and starting dose basis

> “Planned dose levels were in the range of 5–150 mg; actual dose levels were 5, 10, 17.5, 25, 50, and 100 mg.”
> “The starting dose was determined based on preclinical data and allometric scaling in accordance with FDA guidance.”
> “Dose escalation was based on the observed safety, pharmacokinetics data, and in vitro TYK2 pharmacodynamic marker levels.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.5-3"></a>

#### Food effect cohort dose of 25 mg fasted and after a high-calorie meal

> “The dose of the study drug was 25 mg (a dose well‐tolerated in a previous cohort) and was administered once fasted and once followed by ingestion of a high‐calorie standard FDA meal (800–1000 kcal).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.5-4"></a>

#### Single ascending dose, food effect, and multiple ascending dose regimens in the ANZCTR record

> “Enrolled participants will be assigned to one of Cohort 1, 2, 3, 4, 5 or 6 will receive a single dose of FTP-637 solution (or placebo) between the dose levels; 5 to 150mg.”
> “Participants will be dosed in the morning following an overnight fast of 10 hours, and will continue to fast for a further 4 hours post dose.”
> “Food effect, cohort 11, receive open label FTP-637 (no placebo) on 2 occasions, once fasted once fed.”
> “The 2 dosing occasions will be separated by 5 days.”
> “Enrolled participants will be assigned to one of Cohort 7, 8, 9, 10 will receive a 7 doses of FTP-637 solution (or placebo) once / twice daily for 7 days.”
> “Dose levels to be evaluated will be in the range of 5 to 150 mg.”
> “Part B participants will be dosed with a meal, preferably at the end of the meal but it may occur during the meal to remain within the required dosing interval.”

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.5-5"></a>

#### Placebo solution in the ANZCTR record

> “A solution containing, Citric Monohydrate, Sodium Citrate Dihydrate, Hypromellose, Betadex Sulfobutyl Ether Sodium, Deionized water, and a bittering agent, Denatonium Benzoate, will be used as the placebo.”

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Safety and Tolerability as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

##### Primary and secondary outcomes in the ANZCTR record

| Outcome | Quoted record |
| --- | --- |
| Primary outcome 1 | “Safety and tolerability of single and 7-day repeat oral doses of FTP-637 as assessed by Adverse Events (assessed accordingly to Common Terminology Criteria for Adverse Events), Physical Examination (change in examination findings), change in weight (digital scale), Vital signs (Blood pressure and heat rate measured using a digital BP monitor), ECG (12 and 5 lead), and Clinical Laboratory parameters (blood biochemistry, hematology and coagulation, and urinalysis).” |
| Secondary outcome 1 | “Pharmacokinetics (PK) of FTP-637 in plasma following administration of single and 7-day repeat oral doses in healthy adult volunteers.” |
| Secondary outcome 2 | “Pharmacokinetics (PK) of FTP-637 as assessed by urine and faeces analysis after a single oral dose in healthy adult volunteers..” |
| Secondary outcome 3 | “Pharmacodynamics (PD) of biomarker changes relevant to the TYK2 pathway associated with administration of FTP-637 in healthy adult volunteers (Part B only). Outcome measured by collection of blood samples.” |
| Secondary outcome 4 | “Exploratory: Effect of FTP-637 on QT interval corrected using the Fridericia method (QTcF) and other ECG parameters, including exposure-related changes in QTcF” |
| Secondary outcome 5 | “Exploratory: Pharmacodynamics (PD) of biomarker changes in Lymphocyte count in plasma, associated with administration of FTP-637 in healthy adult volunteers (Part B only).” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.6.1-2"></a>

##### Adverse event recording period and adverse events expected with TYK2 inhibitors in the ANZCTR record

> “Adverse events will be recorded from the time that a subject signs consent until the final follow up visit.”
> “Adverse events will be assessed by study investigators.”
> “Adverse events known to be associated with tyrosine kinase 2 inhibitors include nasopharyngitis, headache, diarrhea, upper respiratory tract infection, acne and nausea.”

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.6.1-3"></a>

##### Safety assessments in the published report

> “Safety assessments included: (1) recording of treatment‐emergent adverse events (TEAEs) including serious TEAEs, TEAEs leading to death, and TEAEs leading to study drug and/or study discontinuation; (2) clinical laboratory parameters; (3) vital signs; (4) body weight (SAD/MAD); (5) ECG parameters; and (6) physical examinations.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.6.1-4"></a>

##### Pharmacokinetic sampling and urine and feces collection in the single ascending dose part

> “Blood and urine samples were collected predose and at several timepoints postdose.”
> “In the SAD part, urine samples were only collected for the Cohort 50 mg.”
> “Feces were also collected in the SAD/MAD study but not analyzed.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Target and final sample size in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Sample size, target | “96” |
| Sample size, final | “87” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.7.1-2"></a>

##### Participants enrolled in the single and multiple ascending dose parts

> “Ninety‐one participants were enrolled in the SAD/MAD study: 53 in the SAD part (Figure 2) and 38 in the MAD part (Figure S1).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.7.1-3"></a>

##### Absence of a formal sample size calculation

> “No formal sample size calculation was performed.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

##### Safety analysis set

> “The safety analysis was based on all randomized participants who received at least 1 dose of the study drug and had at least 1 postdose safety assessment, and was conducted by actual treatment received.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.7.2-2"></a>

##### Dose proportionality and food effect analyses

> “Dose proportionality was assessed using the power model with linear regression method.”
> “The FE was determined by comparing the PK of ESK‐001 in fed and fasted conditions.”
> “Natural log‐transformed maximum concentration (C max) and area under curve (AUC) were analyzed by an analysis of variance (ANOVA) using PROC MIXED in SAS with treatment, period, and sequence as a fixed effect and participant as a random effect.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

##### Incomplete recruitment of two cohorts during the COVID-19 pandemic

> “Due to the COVID‐19 global pandemic, it was not possible to recruit 8 participants for cohorts 17.5 and 100 mg.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.1-2"></a>

##### Withdrawal of two food effect cohort participants

> “Two participants of the FE cohort discontinued the study drug and study due to TEAEs (see Safety and Tolerability results), that were indicative of a possible COVID‐19 infection, requiring isolation and withdrawal from the study.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

##### Race, ethnicity, sex, and body mass index in the single ascending dose part

> “Most participants were white, not Hispanic or Latin, male in the cohorts receiving ESK‐001 and female in the pooled placebo cohorts (Table S1).”
> “The mean BMI ranged from 21.7 to 26.6 kg/m2.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

##### Absorption, half-life, dose proportionality, and volume of distribution after single doses

> “Following single doses of 5 to 100 mg, ESK‐001 was rapidly absorbed with a median time to C max (T max) of 0.8–1.1 h and showed linear PK characteristics with low variability across the dose cohorts (Figure 3a, Table 1).”
> “The mean terminal half‐life (t ½) was 7.5– 9.3 h and was consistent across the different dose levels.”
> “The AUC from time zero to infinite time (AUC0–inf) and C max increased in a near dose‐proportional manner at doses of 5– 100 mg, and C max plateaued at doses of 50 mg and above, indicating that absorption of ESK‐001 was slowing down at higher doses.”
> “The mean apparent distribution volume during the terminal phase (Vz/F) was high, ranging from 103 to 186 L.”
> “A similar PK profile was observed following multiple doses in the MAD part (Figure S2, Table S3).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.3-2"></a>

##### Plasma pharmacokinetic parameters by single ascending dose and food effect cohort

| Parameter | 5 mg fasted | 10 mg fasted | 17.5 mg fasted | 25 mg fasted | 50 mg fasted | 100 mg fasted | Food effect cohort, 25 mg fasted | Food effect cohort, 25 mg fed |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participants | “5 mg Fasted (N = 6)” | “10 mg Fasted (N = 6)” | “17.5 mg Fasted (N = 4)” | “25 mg Fasted (N = 5)” | “50 mg Fasted (N = 5)” | “100 mg Fasted (N = 5)” | “FE cohort 25 mg Fasted (N = 6)” | “FE cohort 25 mg Fed (N = 6)” |
| Cmax, ng/mL | “38.6 (22)” | “93.0 (28)” | “217 (19)” | “253 (21)” | “603 (24)” | “949 (15)” | “272 (13)” | “131 (22)” |
| Tmax, h | “0.75 (0.75–2.00)” | “0.88 (0.75–4.00)” | “1.13 (0.75–2.00)” | “1.00 (1.00–1.50)” | “1.00 (0.50–1.50)” | “1.00 (0.75–6.00)” | “0.75 (0.50–1.00)” | “4.00 (4.00–6.00)” |
| AUC0–t, h*ng/mL | “326 (29)” | “794 (24)” | “1896 (5)” | “2110 (18)” | “4097 (24)” | “11,092 (14)” | “1829 (13)” | “1802 (20)” |
| AUC0–inf, h*ng/mL | “336 (28)” | “816 (26)” | “1925 (5)” | “2138 (18)” | “4137 (24)” | “11,286 (14)” | “1850 (14)” | “1833 (20)” |
| AUC0–24h, h*ng/mL | “283 (26)” | “675 (18)” | “1662 (4)” | “1873 (20)” | “3678 (21)” | “9379 (14)” | “1642 (13)” | “1550 (20)” |
| t½, h | “8.66 (22)” | “9.26 (18)” | “7.85 (19)” | “7.97 (11)” | “7.48 (10)” | “8.11 (13)” | “7.60 (17)” | “7.91 (14)” |
| CL/F, L/h | “14.9 (36)” | “12.3 (21)” | “9.1 (5)” | “11.7 (17)” | “12.1 (23)” | “8.9 (13)” | “13.5 (13)” | “13.6 (21)” |
| Vz/F, L | “186 (20)” | “164 (13)” | “103 (18)” | “134 (27)” | “130 (14)” | “104 (20)” | “148 (19)” | “156 (28)” |

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

> “Note: All data are reported as geometric mean (CV%) except T max, which was reported as median (minimum–maximum).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.3-3"></a>

##### Urinary excretion of unchanged drug after a single 50 mg dose and multiple doses

> “Urinary excretion of ESK‐001 was minimal following single 50 mg and multiple‐dose administration of ESK‐001, with mean percentage of unchanged drug excreted (%Fe) (coefficient of variation [CV%]) ranging from 0.42% (58%) to 0.93% (49%), and geometric mean renal clearance of unchanged drug from the plasma (CLr) (CV%) ranging from 53.4 (77%) to 101 mL/h (53%).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.3-4"></a>

##### Food effect with the liquid formulation at 25 mg

> “The AUC0–inf was similar under fed and fasted dose administration of 25 mg ESK‐001 (Table 1).”
> “However, C max was reduced by ~50% and median T max increased from 0.75 h to 4 h under fed conditions, indicating that food slowed the absorption of ESK‐001.”
> “Although food slowed the absorption of ESK‐001, data suggest that ESK‐001 may be administered with or without food, as the bioavailability (AUC0–inf) of ESK‐001 was similar under fed and fasted conditions.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.3-5"></a>

##### Pharmacodynamic results of the multiple ascending dose part

> “PD parameters were also assessed in the MAD part of the SAD/MAD study but are not discussed in this article.”
> “Similar results on biomarker changes were observed in the MAD part of the SAD/MAD study (data not shown).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

##### Treatment-emergent adverse events by single ascending dose cohort

| Event | 5 mg fasted (N = 6) | 10 mg fasted (N = 6) | 17.5 mg fasted (N = 4) | 25 mg fasted (N = 6) | 50 mg fasted (N = 6) | 100 mg fasted (N = 5) | Food effect cohort, 25 mg fasted (N = 7) | Food effect cohort, 25 mg fed (N = 7) | Total active (N = 41) | Pooled placebo (N = 12) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participant with at least 1 TEAE | “3 (50.0) [7]” | “3 (50.0) [4]” | “3 (75.0) [8]” | “4 (66.6) [8]” | “6 (100.0) [18]” | “5 (100.0) [22]” | “4 (57.1) [14]” | “4 (57.1) [15]” | “32 (78.0) [96]” | “5 (41.6) [9]” |
| Mild | “3 (50.0) [6]” | “3 (50.0) [4]” | “3 (75.0) [8]” | “4 (66.6) [8]” | “6 (100.0) [18]” | “5 (100.0) [20]” | “4 (57.1) [13]” | “4 (57.1) [13]” | “32 (78.0) [90]” | “5 (41.6) [9]” |
| Moderate | “1 (16.6) [1]” | “0” | “0” | “0” | “0” | “2 (40.0) [2]” | “1 (14.2) [1]” | “2 (28.5) [2]” | “6 (14.6) [6]” | “0” |
| Severe | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| TEAEs considered related to the study drug | “1 (16.6) [2]” | “0” | “3 (75.0) [5]” | “4 (66.6) [6]” | “4 (66.6) [8]” | “5 (100.0) [20]” | “4 (57.1) [5]” | “4 (57.1) [9]” | “25 (60.9) [55]” | “2 (16.6) [3]” |
| TEAEs leading to study drug discontinuation | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “1 (14.2) [1]” | “1 (2.4) [1]” | “0” |
| Any serious TEAE | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| Headache | “0” | “2 (33.3) [2]” | “0” | “2 (33.3) [3]” | “5 (83.3) [5]” | “5 (100.0) [5]” | “3 (42.8) [3]” | “3 (42.8) [6]” | “20 (48.7) [24]” | “3 (25.0) [3]” |
| Dizziness | “0” | “0” | “1 (25.0) [1]” | “0” | “0” | “1 (20.0) [1]” | “0” | “2 (28.5) [2]” | “4 (9.7) [4]” | “0” |
| Fatigue | “0” | “0” | “3 (75.0) [4]” | “0” | “0” | “1 (20.0) [1]” | “0” | “0” | “4 (9.7) [5]” | “1 (8.3) [1]” |
| Nausea | “0” | “0” | “0” | “1 (16.6) [1]” | “2 (33.3) [2]” | “5 (100) [5]” | “1 (14.2) [1]” | “1 (14.2) [1]” | “10 (24.3) [10]” | “0” |
| Catheter site bruise | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “2 (16.6) [2]” |

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

> “Note: All values are n (%) [number of reported TEAEs].”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.5-2"></a>

##### Incidence, severity, relatedness, and discontinuations in the single ascending dose part

> “In the SAD part, 37 (69.8%) participants experienced 105 TEAEs; 32 (78.0%) participants receiving ESK‐001 experienced 96 TEAEs and 5 (41.6%) participants receiving placebo experienced 9 TEAEs.”
> “Most TEAEs (94.3%) were mild in severity and a few moderate in severity (all following administration of ESK‐001).”
> “There were no dose‐related trends in the incidence and severity of TEAEs.”
> “Two participants in the FE cohort discontinued the study drug and study due to TEAEs indicative of a possible COVID‐19 infection, one after 1 dose (fed) in Period 1 due to upper respiratory tract infection, and one after 1 dose (fasted) in Period 1 due to sinus congestion, cough, and sneezing, all mild in severity and not related to study drug.”
> “The most common TEAE (reported in ≥30% of the participants in any group) by preferred term was a headache.”
> “In the cohorts receiving ESK‐001, most TEAEs were considered related to the study drug by the investigator; 25 (61.0%) participants receiving ESK‐001 experienced 55 TEAEs considered related to the study drug.”
> “Two (16.6%) participants receiving placebo experienced 3 TEAEs considered related to placebo.”
> “There were no apparent treatment or dose‐related trends in the clinical laboratory results and no TEAEs arising from abnormalities in clinical laboratory results.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.5-3"></a>

##### Safety in the multiple ascending dose part

> “For the MAD part, a similar safety profile as for the SAD part was observed (Table S6).”
> “One participant receiving ESK‐001 (Cohort 10 mg q.d fasted) discontinued the study drug and study after 1 dose due to TEAEs of nausea and vomiting, both mild in severity and both considered related to study drug.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.5-4"></a>

##### Deaths, serious and severe events, vital signs, and electrocardiograms across both phase 1 studies

> “Overall, there were no deaths, serious TEAEs, nor severe TEAEs reported in either the SAD/MAD or MD studies”
> “No clinically relevant changes were observed in vital signs, ECGs, and physical examination findings.”
> “Additionally, there were no MACE, malignancies, venous thromboembolisms, or adverse trends in laboratory parameters observed, which are commonly associated with non‐selective JAK inhibitors.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.5-5"></a>

##### Cardiac conduction and concentration-QTc analysis

> “Per cardiodynamic analyses, ESK‐001 had no clinically relevant effect on cardiac conduction (i.e., the PR and QRS intervals).”
> “Based on the concentration‐QTc analysis, an effect on the placebo‐corrected change from baseline QTcF (QT interval corrected using Fridericia's method) exceeding 10 ms can be excluded within the observed range of ESK‐001 plasma concentrations up to ~ 1000 ng/mL (data not shown).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary

- The authors note that the study provided short-term exposure data, so chronic effects such as cumulative toxicity were not captured.
- The multiple ascending dose part is reported in supplementary figures and tables, and its biomarker results and the concentration-QTc results are reported as data not shown.
- Participants were healthy adults dosed with a liquid formulation of ESK-001.
- Because of the COVID-19 pandemic, the 17.5 mg and 100 mg cohorts could not be filled to the planned 8 participants (N = 4 and N = 5 in the pharmacokinetic table), and 2 food effect cohort participants withdrew with TEAEs indicative of a possible COVID-19 infection.
- The article and the registry differ: the article reports 91 participants enrolled and a study conducted between January 21, 2021 and February 24, 2022; the ANZCTR record gives a final sample size of 87, a first enrolment on 17/02/2021, and a last data collection on 4/02/2022.
- No formal sample size calculation was performed. Feces were collected but not analyzed, and urine was collected only for the 50 mg cohort of the single ascending dose part.
- The ANZCTR record states that no documents have been uploaded by study researchers and answers No to whether the study will consider sharing individual participant data.

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/); [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.9-2"></a>

#### Short-term exposure in both phase 1 studies

> “Some study limitations should be taken into consideration, including that both the SAD/MAD study and the MD study provided short‐term exposure data, and hence, chronic effects (eg, cumulative toxicity) were not captured (as mentioned above).”
> “However, long‐term safety studies are needed to further evaluate the safety of ESK‐001.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.9-3"></a>

#### Multiple ascending dose part reported only in the supplement

> “As this article focuses on the tablet formulation, details of the MAD part are not discussed in detail.”
> “Study details of the MAD part are described in Appendix S1.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
